Although transmembrane transporters must convert between conformations that bind and release substrates on opposite sides of the membrane, they often have the annoying property of preferring one of those conformations to the other. Obtaining high-resolution structures of transporters reveals one of the conformations, often leaving the other conformation as a matter of speculation. In these cases, the opposite conformation can sometimes be trapped by covalent cross-linking reagents {1} or by mutating the protein so that it prefers a different conformation than the wild type {2}. In this paper, Coleman et al. describe an inward-open conformation of serotonin transporter (SERT) obtained by another method, which depends on the binding of a conformation preferring inhibitor, ibogaine. This current study is a valuable contribution that provides a much-needed structural context for previous computational and functional studies. Previous results with ibogaine established that its binding to SERT stabilized the protein in an inward-facing conformation in which residues lining the cytoplasmic permeation pathway were accessible to aqueous reagents and residues in the extracellular pathway were protected from the same reagents {3}. In contrast, cocaine and antidepressants stabilize SERT in an outward-facing conformation and have the opposite effect on cytoplasmic and extracellular pathway accessibility {4}. SERT conformation is also sensitive to Na+, which stabilizes outward-facing states, as it does with all members of the SLC6 family of neurotransmitter transporters (5). In this paper, Coleman et al. present four cryo-EM structures of human SERT – three in the presence of ibogaine and one in the presence of paroxetine. All of these structures were obtained with a fragment of antigen binding (Fab) fragment that preserved SERT transport activity, and two of them also contained a single chain variable fragment (scFv) that restricts SERT to outward-facing conformations. Outward-facing structures were obtained when both the Fab and scFv were present, one with paroxetine and one with ibogaine. Although density was observed in the central binding sites of these structures, the resolution was too low to identify ibogaine or paroxetine. However, in the paroxetine structure, the location of the density was consistent with previous X-ray structures {6}. Finding ibogaine in the central binding site of outward-facing SERT was surprising in light of previous studies. Not only was this inhibitor thought to stabilize the inward-open conformation, but ibogaine is known to be a non-competitive inhibitor. Binding to the central site of the outward-facing conformation, ibogaine should compete with serotonin (5-HT), in contrast to its known non-competitive inhibitor mode. However, in these structures, SERT was constrained by the scFv to an outward-open conformation, and the affinity of ibogaine binding under these conditions is 10-fold lower than to unconstrained SERT. Thus, the binding site that ibogaine prefers was not available in the outward-open structure because of the conformational constraint. In the structures obtained with only the Fab fragment, the conformations differed from those obtained together with the scFv. In the presence of ibogaine and NaCl, SERT was found in an occluded conformation with ibogaine in the central binding site, but isolated from a narrowed and truncated extracellular pathway, in part by movement of TM6 towards TM8. When NaCl was replaced with KCl, an inward open conformation was observed, with ibogaine bound in almost the same location but with the extracellular pathway closed further by the movement of TM1b towards TM 10 and the cytoplasmic pathway open due to movement of TM1a away from TM8. This conformational change exposes ibogaine to the cytoplasmic pathway. In previous studies with membranes from SERT-expressing cells, dramatic changes in conformation were observed upon ibogaine addition even in NaCl {3,7}. The requirement shown here for removing Na+ in order to observe the inward-facing structure might reflect the different environment of SERT, which here was in detergent solution, but in previous work was in a cell membrane {3}. The overall conformational change from outward- to inward-facing generally resembles the conversion of LeuT from outward- to inward-open conformations. LeuT, a bacterial amino acid transporter, is the only other member of the SLC6 family for which both inward- and outward-open conformations have been observed {2}. The new paper also shows a structure for SERT with the Fab fragment in KCl with noribogaine (a higher-affinity derivative) at lower resolution. Of all the structures in this paper, the ibogaine-bound inward-facing structure has the highest resolution and the noribogaine structure the lowest, although the conformation of the two structures is similar. One feature of the inward-facing structure is of particular significance. In TM5, residues in the cytoplasmic half of the helix, between G278 and P287 partially unwind, disrupting the helical structure. A similar disruption was observed in an occluded X-ray structure of MhsT, a bacterial SERT homolog {8} and recent models derived from hydrogen-deuterium exchange studies with LeuT {9}. As a consequence, the region containing residues T276 and S277 changed from helical in the outward-facing structure to extend in the inward-facing one – exposing both residues to the cytoplasm. This local conformational change supports observations that reactivity of a cysteine replacing S277 provides a sensitive indication of cytoplasmic pathway opening. Moreover, phosphorylation of T276 regulates SERT activity {10} and treatments that favor the inward-facing SERT conformation increase phosphorylation {7}, consistent with the change in secondary structure observed here. Docking and MD simulations were used to model ibogaine into the rather featureless density found in the central substrate site of the ibogaine-SERT complex. Structurally, ibogaine resembles O-methylated 5-HT with an additional ring system linking the amino group with the indole ring. The general orientation of ibogaine in this model is similar to that demonstrated for 5-HT in a previous study {11} and the ibogaine orientation is also similar to that found by induced-fit docking and molecular dynamics simulation in another publication {12}. Moreover, the orientation of docked ibogaine is similar in the outward-facing, occluded and inward-facing cryo-EM structures. These results suggest that SERT conformational changes do not result in dramatic alterations in the substrate binding site. Nevertheless, the decrease in ibogaine affinity when SERT is restricted to an outward-facing conformation and the observation that ibogaine stabilizes an inward-facing conformation is consistent with an influence of conformational changes on binding site geometry that support increased ibogaine affinity in an inward-facing conformation. The authors propose two mechanisms by which ibogaine could inhibit transport. Ibogaine could bind from the external medium to produce an intermediate like the conformationally restricted outward-facing structure, followed by extracellular pathway closing to form first the occluded NaCl structure and then the inward-facing KCl structure. This possibility is contradicted by the ibogaine inhibition kinetics which are strictly non-competitive in uptake experiments {3,13,14}. Non-competitive inhibition suggests that binding from the outside represents a negligible fraction of the inhibition because ibogaine would have to compete with 5-HT for the central binding site. Slow dissociation of ibogaine might obscure such competition with 5-HT, but this is unlikely because ibogaine dissociates as fast as cocaine, which is a competitive inhibitor {13}. The alternative is that ibogaine could cross the membrane by non-ionic diffusion – it is known to be highly permeant {15} – and bind to SERT from the cytoplasm. However, the cytoplasmic permeation pathway seems too small to allow ibogaine binding without opening wider than shown in this structure and some experiments suggest that cytoplasmic ibogaine does not inhibit SERT {13}. It seems quite likely that ibogaine at the central binding site of SERT is responsible for its conformational influence on the transporter. How it gets there is still a matter for debate.